title: Mice fed lipid-encapsulated Mycobacterium bovis BCG are protected against aerosol challenge with Mycobacterium tuberculosis.
abstract: Mice that consumed a single dose of 10(7) lipid-encapsulated Mycobacterium bovis BCG bacilli showed significant pulmonary and systemic protection against aerosol challenge with M. tuberculosis H37Rv. As an extension of previous challenge studies with virulent strains of M. bovis, this report describes a reduction in M. tuberculosis infection in mice vaccinated orally with lipid-encapsulated BCG comparable to that observed in mice vaccinated subcutaneously with BCG. These results are consistent with the induction of tuberculin-specific cell-mediated immune responses.
authors.affiliation: Department of Microbiology and Immunology, University of Otago, P.O. Box 56, Dunedin, New Zealand. frank.aldwell@stonebow.otago.ac.nz.
authors.forename: Frank E
authors.initials: FE
authors.lastname: Aldwell
authors.forename: Lise
authors.initials: L
authors.lastname: Brandt
authors.forename: Clare
authors.initials: C
authors.lastname: Fitzpatrick
authors.forename: Ian M
authors.initials: IM
authors.lastname: Orme
mesh_terms: D000284:Administration, Oral; D000336:Aerosols; D000818:Animals; D001500:BCG Vaccine / Q000008:administration & dosage* / Q000737:chemistry* / Q000276:immunology; D002214:Capsules; D002417:Cattle; D007114:Immunization; D008055:Lipids; D008168:Lung / Q000382:microbiology; D051379:Mice; D008810:Mice, Inbred C57BL; D009169:Mycobacterium tuberculosis / Q000276:immunology* / Q000472:pathogenicity; D013154:Spleen / Q000382:microbiology; D014397:Tuberculosis, Pulmonary / Q000382:microbiology / Q000517:prevention & control*
chemical_list: D000336:Aerosols; D001500:BCG Vaccine; D002214:Capsules; D008055:Lipids
references.citation: Vaccine. 2000 Jan 18;18(13):1186-95
references.pmid: 10649619
references.citation: Dev Biol Stand. 1996;87:251-61
references.pmid: 8854025
references.citation: Clin Infect Dis. 2000 Jun;30 Suppl 3:S299-301
references.pmid: 10875804
references.citation: Infect Immun. 2001 May;69(5):3264-70
references.pmid: 11292749
references.citation: Infect Immun. 2002 Mar;70(3):1566-70
references.pmid: 11854245
references.citation: Infect Immun. 2002 Jun;70(6):3111-21
references.pmid: 12011005
references.citation: Infect Immun. 2003 Jan;71(1):101-8
references.pmid: 12496154
references.citation: Gene Ther. 2003 Apr;10(8):678-85
references.pmid: 12692596
references.citation: Vaccine. 2003 Dec 8;22(1):70-6
references.pmid: 14604573
references.citation: Infect Immun. 2004 Jan;72(1):238-46
references.pmid: 14688101
references.citation: J Immunol. 2004 Jun 15;172(12):7618-28
references.pmid: 15187142
references.citation: Scand J Immunol. 2004 Sep;60(3):273-7
references.pmid: 15320884
references.citation: Infect Immun. 1984 Apr;44(1):28-32
references.pmid: 6423543
references.citation: Bull World Health Organ. 1994;72(2):213-20
references.pmid: 8205640
references.citation: Infect Immun. 1996 Jan;64(1):1-9
references.pmid: 8557324
references.citation: Clin Infect Dis. 2000 Jun;30 Suppl 3:S217-22
references.pmid: 10875787